Identification of osteopontin as a prognostic plasma marker for head and neck squamous cell carcinomas.
about
HLA class I and II genotype of the NCI-60 cell linesPathophysiological Basis for the Formation of the Tumor MicroenvironmentOPN -RevisitedPlasma osteopontin levels in patients with head and neck cancer and cervix cancer are critically dependent on the choice of ELISA system.Development of fragment-specific osteopontin antibodies and ELISA for quantification in human metastatic breast cancerThe RGD domain of human osteopontin promotes tumor growth and metastasis through activation of survival pathwaysReduction of elevated plasma osteopontin levels with resection of non-small-cell lung cancer.Clinical biomarkers for hypoxia targetingEffects of osteopontin inhibition on radiosensitivity of MDA-MB-231 breast cancer cellsDiscovery of prognostic factors for diagnosis and treatment of epithelial-derived ovarian cancer from laying hens.Aberrant expression of osteopontin and E-cadherin indicates radiation resistance and poor prognosis for patients with cervical carcinomaRole of the integrin-binding protein osteopontin in lymphatic metastasis of breast cancer.Prognostic significance of plasma osteopontin in patients with locoregionally advanced head and neck squamous cell carcinoma treated on TROG 02.02 phase III trial.Opportunities and challenges facing biomarker development for personalized head and neck cancer treatment.Role of osteopontin in tumour progression.Expression profiling in ovarian clear cell carcinoma: identification of hepatocyte nuclear factor-1 beta as a molecular marker and a possible molecular target for therapy of ovarian clear cell carcinomaExpression of Osteopontin in Oral Squamous Cell Carcinoma and its Surgical Margins-An Immunohistochemical Study.A perspective on DNA microarrays in pathology research and practiceOsteopontin and thrombospondin-1 play opposite roles in promoting tumor aggressiveness of primary resected non-small cell lung cancer.Osteopontin Fragments with Intact Thrombin-Sensitive Site Circulate in Cervical Cancer PatientsStrategic plans to promote head and neck cancer translational research within the radiation therapy oncology group: a report from the translational research programNew developments in radiation therapy for head and neck cancer: intensity-modulated radiation therapy and hypoxia targeting.A novel aldehyde dehydrogenase-3 activator (Alda-89) protects submandibular gland function from irradiation without accelerating tumor growthLower osteopontin plasma levels are associated with superior outcomes in advanced non-small-cell lung cancer patients receiving platinum-based chemotherapy: SWOG Study S0003Extracellular and intracellular mechanisms that mediate the metastatic activity of exogenous osteopontin.Molecular aspects of tumour hypoxia.Expression profiling of cervical cancers in Indian women at different stages to identify gene signatures during progression of the disease.Identification of a biomarker panel using a multiplex proximity ligation assay improves accuracy of pancreatic cancer diagnosis.The tumor microenvironment in non-small-cell lung cancerIndividualization of cancer treatment from radiotherapy perspective.Hypoxia in cervical cancer: from biology to imaging.Evaluating the efficacy of osteopontin expression as a prognostic marker in oral squamous cell carcinoma in the Indian subpopulation.Genome-wide analysis of p53 under hypoxic conditions.Identifying and targeting hypoxia in head and neck cancer: a brief overview of current approaches.Correlation of hypoxia status with radiosensitizing effects of sodium glycididazole: A preclinical study.
P2860
Q24805062-4085973B-F387-4149-8A10-20C04C94538DQ26752406-3A79EFC7-2BC5-4844-9695-40E318BAE6D4Q26798763-531D2A24-26AB-463E-88E7-37DA0A2644D8Q33254071-11DA655B-C08D-48A4-B64B-9157A62F3A13Q33317638-6B5A1CCE-877E-42CE-8662-C49F45CA8C22Q33540190-23A43EC3-D84D-4E69-89A8-51E98DBCB99DQ33710746-DAFD0F27-E85E-44B2-9C03-B9A359A69D56Q33714638-D2AEC9A3-CB32-4B56-86D0-1FEA4570A3CDQ34173692-6F307927-0B5C-4D98-8CF2-9A6947B2E039Q34305434-CC1E5B36-947B-4874-BC07-60C678930FF6Q35009786-2CB38DAC-3264-43C3-A289-5D8FFD68FC36Q35221922-5033A843-DEBF-4FE5-A7AC-5EB6DF729791Q35652920-53445353-D699-4498-83D6-120FD120BF8DQ35673572-6AB6979E-317A-4E7D-A45D-51611E950C73Q35770935-FCC54496-0AB3-46C4-9A8D-9FF3F17CB0E0Q35843312-4C7814A3-580B-4934-90CE-C1DAE1758AE2Q35870989-10F55841-1B73-479F-AC73-FC0A39CF90AAQ35916012-B0E77E29-32C7-4BFD-BA79-A282A33AB6E8Q36079101-D93FAC38-0089-4579-907E-FE6CCB13C272Q36095801-AB49EB3C-F5B2-44EB-A1AE-8E2F6043A075Q36117881-E9605922-8594-4A80-B8A1-11AF5E9F311FQ36807138-23556A99-5591-4946-BB98-BE81D20CD8B4Q37100176-4F5D9720-C0FC-485E-A77C-8D5A50B02749Q37121729-75F5EE78-2486-4425-903D-7DD13630F459Q37344830-3A7A331E-383C-4B30-8E47-B6DAD0D5DBBCQ37453827-DA89471F-B127-444E-8F94-045E4A537AB2Q37481159-04AB9E98-46EC-4DFE-BBDD-11533F400179Q37486590-A9BB885E-DE7C-4778-942B-F7913FB665F3Q37777872-39C83545-037C-474D-9195-51C58F8F8309Q37989616-4F097019-43EB-4E5C-9F47-66E92ED86B89Q38643119-298610DE-EB2B-42D6-A34A-DA271DB8C8AAQ41790196-6233FC3A-591D-4B26-97C0-DCA3C8AB1F26Q42934196-2C563510-E7E6-4FA4-94AC-D16DD5340E36Q43089688-631FD81C-E251-47DF-B5CE-A354B2B4A353Q55230222-61962B04-7526-434F-B40C-AC33B78F311E
P2860
Identification of osteopontin as a prognostic plasma marker for head and neck squamous cell carcinomas.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Identification of osteopontin ...... neck squamous cell carcinomas.
@en
type
label
Identification of osteopontin ...... neck squamous cell carcinomas.
@en
prefLabel
Identification of osteopontin ...... neck squamous cell carcinomas.
@en
P2093
P1476
Identification of osteopontin ...... neck squamous cell carcinomas.
@en
P2093
Albert C Koong
Amato J Giaccia
David J Terris
Harlan A Pinto
Ho Sheng Lin
Patrick D Sutphin
Quynh-Thu Le
Sheue Ching T Yu
Soumya Raychaudhuri
P407
P577
2003-01-01T00:00:00Z